Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on May 4, 2023, at 2:30 pm CET to discuss its first quarter 2023 financial results and provide a business update. The event will be available via the Investors section of their website. A replay will be accessible for one year. Dial-in numbers are provided for various countries including the U.S., U.K., and Japan.
As a global immunology company, argenx is focused on severe autoimmune diseases and has partnered with researchers through its Immunology Innovation Program. The company is currently evaluating the therapeutic potential of its approved neonatal Fc receptor (FcRn) blocker and advancing several experimental medicines.